Key result
Novel ERK and BAX inhibitors show preclinical antitumor potential without severe cardiotoxicity.
Why the study?
Cardiovascular toxicity significantly limits the use of antineoplastic agents, motivating the search for anticancer therapeutics without cardiotoxicity.
The emerging field of cardio-oncology focuses on identifying novel anti-cancer therapeutics, such as ERK dimerization inhibitors or BAX allosteric inhibitors, that avoid cardiotoxicity.
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Szabó et al. (2021) conducted a review in Cancer and therapy-related cardiotoxicity. Cardio-safe anticancer therapeutics (ERK dimerization inhibitors and BAX allosteric inhibitors) was evaluated. Newly developed cardio-safe compounds, including ERK dimerization inhibitors and BAX allosteric inhibitors, show preclinical potential to prevent tumorigenesis without causing severe cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: